カレントテラピー　30-10　サンプル page 34/42

このページは カレントテラピー　30-10　サンプル の電子ブックに掲載されている34ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
治療薬解説old：a prospective randomized phase 3 trial from the acuteleukemia French association. Blood 114（abstract 5）：201110）Knapper S：The clinical development of FLT3 inhibitors inacute myeloid....

治療薬解説old：a prospective randomized phase 3 trial from the acuteleukemia French association. Blood 114（abstract 5）：201110）Knapper S：The clinical development of FLT3 inhibitors inacute myeloid leukemia. Expert Opin Investig Drugs 20：1377-1395, 201111）Smith CC, Wang Q, Chin CS, et al：Validation of ITD mutationsin FLT3 as a therapeutic target in human acutemyeloid leukaemia. Nature 485：260-263, 201212）Freeman CL, Swords R, Giles FJ：Amonafide：a future intreatment of resistant and secondary acute myeloid leukemia?Expert Rev Hematol 5：17 -26, 201213）Allen SL, Kolitz JE, Lundberg AS, et al：Phase I trials ofamonafide as monotherapy and in combination with cytarabinein patients with poor -risk acute myeloid leukemia. LeukRes 34：487-491, 201014）Goh BC, Wong AL, Soo RA, et al：Phase I study ofOPB51602, a small molecule inhibitor of STAT3 phosphorylation,in patients with refractory solid malignancies. J ClinOncol 30（suppl；abstr 3002）：201215）Keeton E, Palakurthi S, Alimzhanov M, et al：AZD1208, aNovel, Potent and Selective Pan PIM Kinase Inhibitor,Demonstrates Efficacy in Models of Acute MyeloidLeukemia. Blood 118：（abstract 1540）：201116）Feldman EJ, Lancet JE, Kolitz JE, et al：First-in-man studyof CPX -351：a liposomal carrier containing cytarabine anddaunorubicin in a fixed 5：1 molar ratio for the treatment ofrelapsed and refractory acute myeloid leukemia. J Clin Oncol29：979-985, 201117）Wickstrom M, Larsson R, Nygren P, et al：AminopeptidaseN（CD13）as a target for cancer chemotherapy. Cancer Sci102：501 -508, 201118）Lu DP, Qiu JY, Jiang B, et al：Tetra-arsenic tetra-sulfide forthe treatment of acute promyelocytic leukemia：a pilotreport. Blood 99：3136-3143, 200219）Jabbour E, O’Brien SM, Thomas DA, et al：Inotuzumabozogamycin（I0）, a CD22 monoclonal antibody conjugated tocalecheamicin, given weekly, for refractory -relapse acutelymphocytic leukemia（R-R ALL）. J Clin Oncol 30（suppl；abstr 6501）：201220）Topp M, Goekbuget N, Zugmaier G, et al：Effect of anti -CD19 BiTE blinatumomab on complete remission rate andoverall survival in adult patients with relapsed/refractoryB -precursor ALL. J Clin Oncol 30（suppl；abstr 6500）：201221）Kalos M, Levine BL, Porter DL, et al：T cells with chimericantigen receptors have potent antitumor effects and canestablish memory in patients with advanced leukemia. SciTransl Med 3：95ra73, 201122）Brentjens RJ, Riviere I, Park JH, et al：Safety and persistenceof adoptively transferred autologous CD19-targeted Tcells in patients with relapsed or chemotherapy refractoryB-cell leukemias. Blood 118：4817-4828, 201123）Lowenberg B, Muus P, Ossenkoppele G, et al：Phase 1/2study to assess the safety, efficacy, and pharmacokinetics ofbarasertib（AZD1152）in patients with advanced acutemyeloid leukemia. Blood 118：6030-6036, 201124）Schoffski P：Polo -like kinase（PLK）inhibitors in preclinicaland early clinical development in oncology. Oncologist 14：559-570, 200925）Seetharam M, Fan AC, Tran M, et al：Treatment of higherrisk myelodysplastic syndrome patients unresponsive tohypomethylating agents with ON 01910.Na. Leuk Res 36：98 -103, 201226）Hawtin RE, Stockett DE, Byl JA, et al：Voreloxin is an anticancerquinolone derivative that intercalates DNA and poisonstopoisomeraseⅡ. PLoS One 5：e10186, 201027）Lowenberg B, Morgan G, Ossenkoppele GJ, et al：Phase I/Ⅱclinical study of Tosedostat, an inhibitor of aminopeptidases,in patients with acute myeloid leukemia and myelodysplasia.J Clin Oncol 28：4333-4338, 201028）Altman JK, Sassano A, Platanias LC：Targeting mTOR forthe treatment of AML. New agents and new directions.Oncotarget 2：510 -517, 201129）Kantarjian H, Thomas D, Jorgensen J, et al：Inotuzumabozogamicin, an anti -CD22 -calecheamicin conjugate, forrefractory and relapsed acute lymphocytic leukaemia：aphase 2 study. Lancet Oncol 13：403-411, 201230）Klinger M, Brandl C, Zugmaier G, et al：Immunopharmacologicresponse of patients with B-lineage acute lymphoblastic leukemiato continuous infusion of T cell -engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 119：6226-6233,201231）Topp MS, Kufer P, Gokbuget N, et al：Targeted therapywith the T -cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B -lineageacute lymphoblastic leukemia patients results in highresponse rate and prolonged leukemia-free survival. J ClinOncol 29：2493-2498, 201132）Porter DL, Levine BL, Kalos M, et al：Chimeric antigenreceptor?modified T cells in chronic lymphoid leukemia. NEngl J Med 365：725-733, 201133）Kantarjian H, Gandhi V, Cortes J, et al：Phase 2 clinical andpharmacologic study of clofarabine in patients with refractoryor relapsed acute leukemia. Blood 102：2379-2386, 200334）Faderl S, Gandhi V, O’Brien S, et al：Results of a phase 1 -2study of clofarabine in combination with cytarabine（ara-C）in relapsed and refractory acute leukemias. Blood 105：940 -947, 200535）Faderl S, Verstovsek S, Cortes J, et al：Clofarabine and cytarabinecombination as induction therapy for acute myeloidleukemia（AML）in patients 50 years of age or older. Blood108：45-51, 200636）Burnett A, Baccarani M, Johnson P, et al：A phaseⅡstudy（Biov-121）of clofarabine monotherapy first line in patientsaged 65 years or older with acute myeloid leukemia forwhom standard intensive chemotherapy is not consideredsuitable. Blood 108：（abstract 1985）：200637）Silverman LR, McKenzie DR, Peterson BL, et al；Cancer andLeukemia Group B：Further analysis of trials with azacitidinein patients with myelodysplastic syndrome：studies8421, 8921, and 9221 by the Cancer and Leukemia Group B. JClin Oncol 24：3895-3903, 200638）Kantarjian HM, O’Brien S, Huang X, et al：Survival advantagewith decitabine versus intensive chemotherapy inpatients with higher risk myelodysplastic syndrome：comparisonwith historical experience. Cancer 109：1133 -1137,200739）Lubbert M, Ruter BH, Schmid M, et al：Continued low -doseCurrent Therapy 2012 Vol.30 No.10107993